Inventor · disambiguated record
Satyanarayana Kuchimanchi
Also filed as: KUCHIMANCHI SATYANARAYANA
38 granted patents·24 pending applications·410 citations·filing 2010–2025
98Inventor score
Files withALNYLAM PHARMACEUTICALS INC43ARROWHEAD PHARMACEUTICALS INC5GENZYME CORP3ARROWHEAD RES CORP2BETTENCOURT BRIAN2
Top patents by PatentIndex Score
62 records- 0199US9796974B2Modified RNAi agentsALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Oct 24, 2017·119 cites·30 claims
- 0298US11406716B2Modified RNAi agentsALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Aug 9, 2022·8 cites·21 claims
- 0398US10668170B2Modified RNAi agentsALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Jun 2, 2020·22 cites·22 claims
- 0498US9399775B2RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Jul 26, 2016·51 cites·36 claims
- 0598US9249415B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Feb 2, 2016·24 cites·30 claims
- 0697US11034958B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Jun 15, 2021·7 cites·17 claims
- 0796US11873491B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jan 16, 2024·2 cites·32 claims
- 0896US9850488B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Dec 26, 2017·11 cites·62 claims
- 0996US9701963B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Jul 11, 2017·9 cites·32 claims
- 1096US9127274B2Serpinc1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS·Filed 2013·Granted Sep 8, 2015·51 cites·62 claims
- 1194US11419942B2Angiotensinogen (AGT) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Aug 23, 2022·2 cites·55 claims
- 1294US10570391B2RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Feb 25, 2020·12 cites·45 claims
- 1394US10238749B2Angiotensinogen (AGT) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Mar 26, 2019·12 cites·44 claims
- 1492US10814007B2Angiotensinogen (AGT) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Oct 27, 2020·3 cites·15 claims
- 1591US9376680B2Serpinc1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Jun 28, 2016·7 cites·55 claims
- 1691US9228188B2Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expressionBETTENCOURT BRIAN·Filed 2012·Granted Jan 5, 2016·8 cites·22 claims
- 1790US11162098B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Nov 2, 2021·2 cites·19 claims
- 1890US9725718B2Compositions and methods for inhibition of expression of protein C (PROC) genesALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Aug 8, 2017·3 cites·33 claims
- 1989US11408001B1Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Aug 9, 2022·1 cites·29 claims
- 2089US11142766B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Oct 12, 2021·4 cites·21 claims
- 2189US10407679B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Sep 10, 2019·5 cites·43 claims
- 2289US2025064943A1ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2388US2024279652A1RNAi AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASESALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2488US2025051765A1APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2587US10125369B2PCSK9 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2013·Granted Nov 13, 2018·9 cites·85 claims
- 2687US9970006B2Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genesALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted May 15, 2018·4 cites·15 claims
- 2786US10287582B2Organic compositions to treat HSF1-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted May 14, 2019·3 cites·18 claims
- 2886US2024110180A1Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genesALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2985US9540643B2Organic compositions to treat HSF1-related diseasesARROWHEAD RES CORP·Filed 2015·Granted Jan 10, 2017·3 cites·21 claims
- 3085US9068184B2Compositions and methods for inhibition of expression of protein C (PROC) genesTOUDJARSKA IVANKA·Filed 2012·Granted Jun 30, 2015·5 cites·24 claims
- 3185US8481509B2Organic compositions to treat HSF1-related diseasesHINKLE GREGORY·Filed 2012·Granted Jul 9, 2013·6 cites·20 claims
- 3285US2023365965A1SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOFGENZYME CORP·Filed 2023·Application pending·0 cites
- 3384US12290573B2Modified RNAi agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted May 6, 2025·0 cites·20 claims
- 3484US8293718B2Organic compositions to treat HSF1-related diseasesHINKLE GREGORY·Filed 2010·Granted Oct 23, 2012·5 cites·51 claims
- 3583US12091661B2Organic compositions to treat HSF1-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Sep 17, 2024·0 cites·20 claims
- 3683US9096637B2Organic compositions to treat HSF1-related diseasesARROWHEAD RES CORP·Filed 2013·Granted Aug 4, 2015·3 cites·22 claims
- 3783US2025270555A1Organic compositions to treat beta-catenin-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3882US8623838B2Organic compositions to treat HSF1-related diseasesCHEN JINYUN·Filed 2012·Granted Jan 7, 2014·6 cites·22 claims
- 3982US2025213720A1MODIFIED RNAi AGENTSALNYLAM PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 4082US2023068339A1APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4181US2023123192A1ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4280US9315813B2Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genesBETTENCOURT BRIAN·Filed 2012·Granted Apr 19, 2016·3 cites·17 claims
- 4378US11118181B2Compositions and methods for inhibition of expression of protein C (PROC) genesALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Sep 14, 2021·0 cites·20 claims
- 4478US2021388360A1Compositions and methods for inhibition of expression of protein c (proc) genesALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4577US11091761B2Organic compositions to treat HSF1-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Aug 17, 2021·0 cites·20 claims
- 4677US2023010288A1Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4777US2022049253A1Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genesALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4876US2020263176A1Compositions and Methods for Inhibition of Expression of Apolipoprotein C-III (APOC3) GenesALNYLAM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4976US2021254063A1SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOFGENZYME CORP·Filed 2020·Application pending·0 cites
- 5074US12460206B2PCSK9 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Nov 4, 2025·0 cites·2 claims
Showing the top 50 of 62 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Satyanarayana Kuchimanchi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →